REG - GSK PLC - Positive data for low carbon version Ventolin MDI

GSKAnnouncement

Yesterday 07:05

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251022:nRSV2967Ea&default-theme=true

RNS Number : 2967E  GSK PLC  22 October 2025

Issued: 22 October 2025, London UK

 

GSK announces positive pivotal phase III data for next-generation low carbon
version of Ventolin (salbutamol) metered dose inhaler

 

·   Data confirm therapeutic equivalence and comparable safety profile for
Ventolin (salbutamol) containing innovative low carbon propellant

·   Approximately 300 million salbutamol MDIs are sold globally every
year(1,2)

·   If approved, this next-generation low carbon salbutamol has the
potential to reduce greenhouse gas emissions by 92%(3) per inhaler

·   GSK will proceed with regulatory submissions, with launch expected from
2026

 

GSK plc (LSE/NYSE: GSK) today announced positive phase III data from its
clinical programme to develop a next-generation version of its metered dose
inhaler (MDI), Ventolin (salbutamol). Data confirm that the formulation of
salbutamol MDI containing an innovative low carbon propellant HFA-152a shows
therapeutic equivalence and is comparable in safety to salbutamol MDI
containing the current propellant, HFA-134a.

 

The findings will support regulatory submissions for the next-generation
version, with launch expected from 2026, an important advance to bringing a
more sustainable option to patients with respiratory disease.

 

Nearly half a billion people are affected by asthma and chronic obstructive
pulmonary disease (COPD) around the world(4) and approximately 300 million
salbutamol MDIs are sold globally every year(1,2). Used during an
exacerbation, or "attack", salbutamol in an MDI can help by immediately
treating a sudden onset of respiratory symptoms, such as breathlessness.

 

Kaivan Khavandi, SVP, Global Head, Respiratory, Immunology & Inflammation
R&D, GSK, said: "Healthy air is essential for healthy lungs, and our
next-generation salbutamol has the potential to reduce greenhouse gas
emissions by 92%(3) per inhaler. Almost six decades after its first
development, this medicine remains highly valued by patients and healthcare
professionals and is a key component of our respiratory portfolio. Today, we
are one step closer to a reliever MDI that we believe will continue to help
patients for many decades to come."

 

Due to the scale of volume and worldwide use, GSK's salbutamol MDI currently
accounts for close to half (45%)(5) of the company's total global carbon
footprint. GSK has partnered to use cutting-edge propellant technologies to
develop a next-generation low-carbon version and has added advanced
manufacturing technologies to support launch of this inhaler.

 

Prof. Ashley Woodcock, Professor of Respiratory Medicine at the University of
Manchester, said: "While low carbon alternatives already exist, such as dry
powder and soft mist inhalers, we know that many patients worldwide with both
asthma and COPD prefer a salbutamol MDI to relieve their symptoms. These data
should enable patients to use their preferred inhaler choice. This is a
crucial advance to help global healthcare systems meet their climate targets
at the same time as optimising the care of patients."

 

About inhaled medicines

Inhaled medicines are administered to the lungs using an inhaler device. There
are two main types of devices, metered dose inhalers (MDIs) and dry power
inhalers (DPIs). All MDIs use a propellant to administer the medicine from the
inhaler into the patient's lungs. DPIs are propellant free, as the medicine is
administered by the patients breathing in the powder, and therefore have a
lower carbon impact compared to MDIs still using high global warming potential
(GWP) propellants.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 

 

 GSK enquiries
 Media:                 Simon Steel        +44 (0) 20 8047 5502  (London)
                        Sarah Clements     +44 (0) 20 8047 5502  (London)
                        Kathleen Quinn     +1 202 603 5003       (Washington DC)
                        Lyndsay Meyer      +1 202 302 4595       (Washington DC)

 Investor Relations:    Constantin Fest    +44 (0) 7831 826525   (London)
                        James Dodwell      +44 (0) 20 8047 2406  (London)
                        Mick Readey        +44 (0) 7990 339653   (London)
                        Steph Mountifield  +44 (0) 7796 707505   (London)
                        Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                        Frannie DeFranco   +1 215 751 3126       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q2 Results for 2025.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

References

1 IQVIA; Data on file 2025.

2 MCTOC; 2022 Assessment Report MCTOC-Assessment-Report-2022.pdf
(https://ozone.unep.org/system/files/documents/MCTOC-Assessment-Report-2022.pdf)
(p16)

3 Plank et al. 2025. Decarbonizing Respiratory Care: The Impact of a
Low-carbon Salbutamol Metered-dose Inhaler. ATS Journal. A1082-A7905
(https://www.atsjournals.org/doi/abs/10.1164/ajrccm.2025.211.Abstracts.A5548)
: Life cycle assessment completed across seven countries for the year 2023
[Algeria, Australia, Canada, France, Poland, Romania, and Saudi Arabia].

4 The Lancet; May 2023. Global burden of chronic respiratory diseases and risk
factors, 1990-2019: an update from the Global Burden of Disease Study 2019.

5 GSK Annual Report 2024
https://www.gsk.com/media/vounsu2k/strategic-report-2024.pdf
(https://www.gsk.com/media/vounsu2k/strategic-report-2024.pdf) (p69)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDDBDGXDDDGUB



            Copyright 2019 Regulatory News Service, all rights reserved